Takeda Pharmaceutical Co. announced that the U.S. FDA approved the lung cancer drug it recently acquired from the the drug developer, Ariad Pharmaceuticals Inc.
The drug, Alunbrig, has been approved as a second-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer, who have progressed on or are intolerant to Pfizer's crizotinib, the standard initial treatment for the disease, according to a Reuters article.
Alunbrig was approved under the FDA's accelerated approval program, which allows for faster drug approval when that drug fills an unmet medical need. The company must provide further evidence of its benefit, or the approval can possibly be revoked, the story said.
Read the full story
